Winner Medical Co., Ltd. (300888.SZ)
CNY 52.22
(0.27%)
CNY 52.22
(0.27%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.4 Billion CNY | -56.6% |
| 2022 | 2.52 Billion CNY | 46.57% |
| 2021 | 1.92 Billion CNY | -60.3% |
| 2020 | 4.76 Billion CNY | 546.5% |
| 2019 | 806.18 Million CNY | 19.41% |
| 2018 | 586.36 Million CNY | 0.03% |
| 2017 | 583.56 Million CNY | 24.35% |
| 2016 | 531.77 Million CNY | 65.93% |
| 2015 | 310.06 Million CNY | 49.83% |
| 2014 | 206.93 Million CNY | 69.43% |
| 2013 | 122.13 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 242.58 Million CNY | 114.39% |
| 2024 Q3 | 226.85 Million CNY | -46.99% |
| 2024 Q2 | 341.63 Million CNY | 78.87% |
| 2023 Q1 | 515.27 Million CNY | -38.54% |
| 2023 Q4 | -66.09 Million CNY | -146.11% |
| 2023 FY | - CNY | -56.6% |
| 2023 Q3 | 143.34 Million CNY | -66.77% |
| 2023 Q2 | 431.33 Million CNY | -16.29% |
| 2022 Q4 | 838.32 Million CNY | 104.14% |
| 2022 Q3 | 410.65 Million CNY | -41.63% |
| 2022 Q2 | 703.57 Million CNY | 59.87% |
| 2022 Q1 | 440.08 Million CNY | 48.27% |
| 2022 FY | - CNY | 46.57% |
| 2021 FY | - CNY | -60.3% |
| 2021 Q3 | 334.76 Million CNY | -6.06% |
| 2021 Q4 | 296.81 Million CNY | -11.34% |
| 2021 Q1 | 596.47 Million CNY | -33.89% |
| 2021 Q2 | 356.35 Million CNY | -40.26% |
| 2020 Q2 | 875.69 Million CNY | 114.6% |
| 2020 FY | - CNY | 546.5% |
| 2020 Q1 | 408.05 Million CNY | 133.43% |
| 2020 Q3 | 2.59 Billion CNY | 196.38% |
| 2020 Q4 | 902.23 Million CNY | -65.24% |
| 2019 Q4 | 174.8 Million CNY | -15.98% |
| 2019 FY | - CNY | 19.41% |
| 2019 Q3 | 208.05 Million CNY | 29.5% |
| 2019 Q2 | 160.65 Million CNY | -0.0% |
| 2019 Q1 | 160.65 Million CNY | 0.0% |
| 2018 FY | - CNY | 0.03% |
| 2017 FY | - CNY | 24.35% |
| 2016 FY | - CNY | 65.93% |
| 2015 FY | - CNY | 49.83% |
| 2014 FY | - CNY | 69.43% |
| 2013 FY | - CNY | 0.0% |